Obesity-eliminating agent and obesity-eliminating composition
By using terpene lactone compounds in the underground extract of Peony Wind-proof Peony, it hinders the activity of cyclic AMP-phosphonodiesterase, promotes the differentiation of pre-adipocytes and inhibits fat accumulation, solving the difficulty in developing safe and efficient elimination in the prior art. The problem of obesity agent has achieved excellent obesity reduction results.
Patent Information
- Application Number
- CN202380027151.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-15
- Filing Date
- 2023-02-21
- Publication Date
- 2024-12-06
AI Technical Summary
It is difficult to develop obesity elimination agents and obesity elimination compositions that have excellent obesity elimination effect and high safety, and are particularly suitable as ingredients for beverages, foods, cosmetics, etc.
Using the extract from the underground part of the peony windproof as the main component, the mixture of water and hydrophilic solvents was extracted to obtain terpene lactone compounds such as Hyuganin D, valeric coumarin III, cis-3'-acetyl-4 Extracts of '-Tegatyllactone, trans-3'-acetyl-4'-Chemisolide, isopyrimidine and pterinin, have the ability to hinder the cyclic AMP-phosphonodiesterase activity and promote The effects of pre-adipocyte differentiation, inhibition of fat accumulation and inducing adipocyte death.
It provides obesity elimination agents and obesity elimination compositions with excellent effect on obesity elimination. It is highly safe and suitable for wide application in beverages, foods, cosmetics and other fields, effectively reducing body fat, and is suitable for humans and animals.
Smart Images

Figure GDA0005123079330000121 
Figure GDA0005123079330000141 
Figure GDA0005123079330000161
Abstract
Description
Technical Field
[0001] The present invention relates to an anti-obesity agent and an anti-obesity composition. Background Art
[0002] In recent years, due to lifestyle habits such as overeating and lack of exercise, body fat has increased, and obesity has increased. Such an increase in obesity can be observed not only in humans, but also in pets and poultry. Obesity is the cause of lifestyle diseases such as hyperlipidemia and arteriosclerosis, and therefore has become a major problem not only in terms of beauty but also in terms of health.
[0003] Here, it is known that cyclic AMP (cAMP) participates in the decomposition of fat in the organism. cAMP activates the lipase present in the organism, and fat is decomposed into fatty acids and glycerol by the activated lipase. However, if cAMP-phosphodiesterase is activated, the decomposition of cAMP is induced, which hinders the activation of lipase. Therefore, it is believed that by hindering the activity of cAMP-phosphodiesterase, the cAMP in the cell increases, which can promote the decomposition of fat.
[0004] Attempts have been made to extract substances having a cyclic AMP phosphodiesterase inhibitory effect from natural products. For example, extracts of rattan tea (eg, see Patent Document 1) and extracts of maple plants (see Patent Document 2) have been reported.
[0005] However, there is still a strong demand for new raw materials that have an anti-obesity effect and are highly safe and can be widely used as ingredients for food and beverages, cosmetics, research reagents, etc., and the current situation is that their rapid development is required.
[0006] Prior art literature
[0007] Patent Literature
[0008] Patent Document 1: Japanese Patent Application Publication No. 2003-012532
[0009] Patent Document 2: Japanese Patent Application Publication No. 2003-113068 Summary of the invention
[0010] Problems to be solved by the invention
[0011] The present invention solves the above-mentioned various problems in the past and aims to achieve the following objectives: That is, the present invention aims to provide an anti-obesity agent and an anti-obesity composition having excellent anti-obesity effects and high safety.
[0012] Methods used to solve problems
[0013] In order to solve the above-mentioned problems, the present inventors have repeatedly conducted intensive studies and found that the extract of the underground part of Paeonia suffruticosa has an excellent effect of eliminating obesity and is highly safe, and is useful for eliminating obesity.
[0014] The present invention is based on the above-mentioned knowledge of the present inventors, and as a method for solving the above-mentioned problems, it is as follows. That is,
[0015] <1> An anti-obesity agent, characterized in that it contains an extract from the underground part of Paeonia suffruticosa.
[0016] <2> The anti-obesity agent according to <1> above, wherein the extract from the underground part of Paeonia suffruticosa is an extract obtained using a mixed solvent of water and a hydrophilic solvent.
[0017] <3> The anti-obesity agent according to <1> or <2> above, wherein the extract from the underground part of Paeonia suffruticosa contains, as terpene lactones, Hyuganin D, diazepam III, cis-3'-acetyl-4'-tegumentyl lactone, trans-3'-acetyl-4'-senecioide, isopyrimidine, and pterin.
[0018] <4> The anti-obesity agent according to any one of <1> to <3> above, which has one or more effects selected from the group consisting of cyclic AMP-phosphonodiesterase activity inhibitory effect, preadipocyte differentiation induction promoting effect, fat accumulation inhibitory effect and adipocyte cell death induction effect.
[0019] <5> A composition for eliminating obesity, comprising the anti-obesity agent according to any one of <1> to <4> above.
[0020] Effects of the Invention
[0021] The anti-obesity agent and the anti-obesity composition of the present invention can solve the above-mentioned problems in the past, achieve the above-mentioned objects, and provide an anti-obesity agent and an anti-obesity composition having excellent anti-obesity effects and high safety. DETAILED DESCRIPTION
[0022] (Obesity Elimination Agent)
[0023] The anti-obesity agent of the present invention contains the extract of the base of Paeonia suffruticosa peony as an active ingredient, and further contains other ingredients as necessary.
[0024] In this specification, "obesity" refers to a state in which body fat is excessively accumulated. In addition, in this specification, "eliminating obesity" refers to reducing the excessively accumulated body fat to a state close to normal. In addition, reducing body fat to a state close to normal by preventing the increase or accumulation of body fat is also included in "eliminating obesity". In addition, the amount of body fat does not need to be restored to a normal state, but at least the amount of body fat can be reduced from a state of excessive accumulation.
[0025] The details of the substance that has the effect of eliminating obesity in the extract of the above-mentioned underground part of Paeonia suffruticosa are still unclear. It was previously completely unknown that the extract of the above-mentioned underground part of Paeonia suffruticosa has an excellent effect of eliminating obesity and is useful as an anti-obesity agent. This is a new understanding of the present inventors.
[0026] <Extract from the underground part of Paeonia suffruticosa>
[0027] The above-mentioned Peucedanum japonicum Thunb. is a plant of the genus Peucedanum of the Apiaceae family, is a perennial herb growing along the coast, and is distributed in countries or regions such as west of Kanto, Shikoku, Kyushu Island, Okinawa, Korea, China, and the Philippines, and can be easily obtained from these regions.
[0028] The extract of the above-mentioned Paeonia suffruticosa root base may be an extract prepared from an extraction part used as an extraction raw material, and a commercially available product may be used.
[0029] The extraction part of the above-mentioned Paeonia suffruticosa is not particularly limited as long as it is an underground part, and can be appropriately selected according to the purpose, and examples thereof include roots, rhizomes, etc. These may be used alone or in combination of two or more.
[0030] The shape, structure, and size of the extracting material of Paeonia suffruticosa are not particularly limited and can be appropriately selected according to the intended purpose.
[0031] There is no particular limitation on the method for preparing the extract of the Radix Paeoniae suffruticosae var. truncatum. The method can be appropriately selected according to the purpose, and for example, a method in which the extract is dried and then directly or by using a coarse crusher for crushing can be mentioned. The dried product can be directly supplied or the crushed product can be supplied to solvent extraction. The drying can be carried out in the sun or by using a commonly used drying machine.
[0032] The extract of the above-mentioned peony siler underground part can be easily obtained by the method generally used by the extraction of plants. As the mode of the extract of the above-mentioned peony siler underground part, there is no particular restriction, can be suitably selected according to purpose, for example, can enumerate extract itself, the diluent of extract, the concentrated solution of extract, their dried products, crude refined products, refined products etc.
[0033] The extraction method is not particularly limited and can be appropriately selected according to the purpose. For example, a method of extracting at room temperature or under reflux heating using any extraction device can be cited. More specifically, a method of putting the above-mentioned extracted part of Paeonia suffruticosa as an extraction raw material into a treatment tank filled with an extraction solvent, stirring appropriately as needed, and standing for 30 minutes to 4 hours, for example, to dissolve the soluble components, and then filtering to remove the extraction residue to obtain an extract, etc. The extraction solvent can be further distilled off the above-mentioned extract and dried.
[0034] In addition, the raw material can be used as an extraction material after being subjected to pretreatment such as defatting with a non-polar solvent such as hexane. By performing pretreatment such as defatting, extraction treatment with a polar solvent can be performed efficiently.
[0035] The conditions (extraction time and extraction temperature) for extracting the peony flavonoids, the extraction solvent, and the amount of the extraction solvent used are not particularly limited and can be appropriately selected depending on the intended purpose.
[0036] As the above-mentioned extraction solvent, there is no particular limitation and it can be appropriately selected according to the purpose, and for example, water, a hydrophilic solvent, or a mixed solvent of water and a hydrophilic solvent can be mentioned. Among these, a mixed solvent of water and a hydrophilic solvent is preferably used because the anti-obesity effect of the extract is more excellent.
[0037] As the above-mentioned water, there is no particular restriction, and it can be appropriately selected according to the purpose. For example, in addition to pure water, tap water, well water, mineral water, mineral water, hot spring water, spring water, fresh water, etc., the products implemented with various treatments are also included. As the treatment implemented for water, for example, it includes refining, heating, sterilization, filtration, ion exchange, adjustment of osmotic pressure, buffering, etc. In addition, the water that can be used as the above-mentioned extraction solvent also includes purified water, hot water, ion exchange water, physiological saline, phosphate buffer, phosphate buffered saline, etc. The above-mentioned water can be used alone or in combination of two or more.
[0038] The hydrophilic solvent is not particularly limited and can be appropriately selected according to the purpose, and examples thereof include lower alcohols having 1 to 5 carbon atoms, such as methanol, ethanol, propanol, and isopropanol; lower aliphatic ketones, such as acetone and methyl ethyl ketone; polyols having 2 to 5 carbon atoms, such as 1,3-butanediol, propylene glycol, and glycerol, etc. These may be used alone or in combination of two or more.
[0039] The amount of the hydrophilic solvent used in the mixed solvent relative to the water is not particularly limited and can be appropriately selected according to the purpose. When using a lower alcohol, it is preferably added in an amount of 1 to 90 parts by volume relative to 10 parts by volume of water. When using a lower aliphatic ketone, it is preferably added in an amount of 1 to 40 parts by volume relative to 10 parts by volume of water. When using a polyol, it is preferably added in an amount of 1 to 90 parts by volume relative to 10 parts by volume of water.
[0040] The temperature of the extraction solvent is not particularly limited and can be appropriately selected depending on the intended purpose, but is preferably used at a temperature from room temperature to a temperature below the boiling point of the solvent.
[0041] The extract of the underground part of Paeonia suffruticosa obtained can be diluted, concentrated, dried, purified, etc. by conventional methods to obtain a diluted, concentrated, dried, crudely purified, purified, etc. extract of the underground part of Paeonia suffruticosa.
[0042] As the purification method of the extract of the above-mentioned Paeonia suffruticosa underground part, there is no particular restriction, and it can be appropriately selected according to the purpose, and for example, purification methods such as activated carbon treatment, adsorption resin treatment, ion exchange resin treatment can be enumerated. Refined by the above-mentioned purification method, it is possible to increase the concentration of the active ingredient, or remove waste.
[0043] The extract of the above-mentioned Paeonia suffruticosa underground part obtained can also be directly used as the above-mentioned anti-obesity agent. From the perspective of easy utilization, it is preferably the above-mentioned concentrated solution or the above-mentioned dried product. When obtaining the above-mentioned dried product, a carrier such as dextrin or cyclodextrin can be added to improve hygroscopicity.
[0044] The extract of the underground part of Paeonia suffruticosa is preferably in a form containing Hyuganin D (hyuganinD), peucedanocoumarin III (peucedanocoumarin III), cis-3'-acetyl-4'-tigloylkhellactone (cis-3'-acetyl-4'-tigloylkhellactone), trans-3'-acetyl-4'-senecioylkhellactone (trans-3'-acetyl-4'-senecioylkhellactone), isosamidin (isosamidin), and pteryxin (pteryxin) as terpene lactones, in view of its better effect in eliminating obesity.
[0045] The total content of the terpene lactones in the extract of the underground parts of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose, but is preferably 1% by mass to 5% by mass, and more preferably 2.5% by mass to 5% by mass.
[0046] The content of the Hyuganin D in the extract of the underground parts of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose. For example, 0.04% by mass to 0.5% by mass can be mentioned.
[0047] The content of the above-mentioned stable coumarin III in the above-mentioned extract of the underground part of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose. For example, 0.1 mass % to 1.0 mass % may be mentioned.
[0048] The content of the cis-3'-acetyl-4'-tegumentyl lactone in the extract of the underground parts of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose. For example, the content is 0.01% by mass to 0.5% by mass.
[0049] The content of the trans-3'-acetyl-4'-seneciolide in the extract of the underground parts of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose, but is preferably 0.05 to 2.5% by mass, more preferably 0.3 to 2.0% by mass.
[0050] The content of the isopyrimidine in the extract of the underground part of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose, but is preferably 0.01% by mass to 0.5% by mass, and more preferably 0.05% by mass to 0.4% by mass.
[0051] The content of the pterin in the extract of the underground part of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose. For example, 0.5% by mass to 5% by mass can be mentioned.
[0052] The method for measuring the content of the terpene lactones in the extract of the underground part of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose. For example, the method described in Test Example 1-1 described later can be mentioned.
[0053] The extract of the underground part of Paeonia suffruticosa may contain chlorogenic acid and rutin.
[0054] The content of the chlorogenic acid in the extract of the underground part of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose, but is preferably 1.0 mass % or less, and more preferably 0.05 mass % to 0.8 mass %.
[0055] The content of the rutin in the extract of the underground parts of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose, but is preferably 0.1% by mass or less, and more preferably 0.001% by mass to 0.05% by mass.
[0056] The method for measuring the contents of the chlorogenic acid and the rutin in the extract of the underground part of Paeonia suffruticosa is not particularly limited and can be appropriately selected depending on the purpose. For example, the method described in Test Example 1-2 described later may be mentioned.
[0057] The content of the extract of the peony siamese underground part in the anti-obesity agent is not particularly limited and can be appropriately adjusted according to the physiological activity of the extract of the peony siamese underground part, etc. The anti-obesity agent may be formed only of the extract of the peony siamese underground part.
[0058] <Other ingredients>
[0059] As the above-mentioned other ingredients, there is no particular restriction, and they can be appropriately selected according to the utilization form of the above-mentioned anti-obesity agent, for example, excipients, antiseptics, reinforcing agents, thickeners, emulsifiers, antioxidants, sweeteners, acidulants, seasonings, coloring materials, spices, whitening agents, humectants, oily components, ultraviolet light absorbers, surfactants, thickeners, alcohols, powdered components, coloring agents, aqueous components, water, skin nutrients, etc. can be enumerated. They can be used alone or in combination of two or more.
[0060] The content of the other components in the anti-obesity agent is not particularly limited and can be appropriately selected depending on the intended purpose.
[0061] <Application>
[0062] The use of the anti-obesity agent is not particularly limited and can be appropriately selected depending on the purpose. Examples thereof include pharmaceuticals, cosmeceuticals, food and beverages, and cosmetics.
[0063] The above-mentioned anti-obesity agent has an excellent anti-obesity effect and is highly safe, and therefore can be suitably used as an active ingredient of an anti-obesity composition, for example.
[0064] The anti-obesity agent of the present invention is suitable for use in humans, but can also be used in animals other than humans (eg, mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as its effects are exerted.
[0065] The administration method of the anti-obesity agent is not particularly limited and can be appropriately selected depending on the intended purpose. Examples of the administration method include oral administration, parenteral administration, and external administration.
[0066] There is no particular limitation on the dosage form of the above-mentioned anti-obesity agent, and it can be appropriately selected according to the purpose. For example, it can include oral administration agents such as tablets, powders, capsules, granules, extracts, and syrups; non-oral administration agents such as injections, drops, and suppositories; external preparations such as lotions, emulsions, creams, ointments, beauty essences, lotions, facial masks, glues, lipsticks, lipsticks, foundations, bath preparations, soaps, shower gels, astringents, hair growth agents, hair conditioners, hair creams, hair dyes, hair conditioners, shampoo, hair dyes, and hair conditioners, etc.
[0067] There are no particular restrictions on the method for producing the anti-obesity agent in each dosage form, and a known method can be appropriately selected.
[0068] There are no particular restrictions on the usage method such as the dosage and period of use of the above-mentioned anti-obesity agent, and it can be appropriately selected according to the purpose.
[0069] Furthermore, the anti-obesity agent of the present invention can also be used as a reagent for research related to the mechanism of action of the anti-obesity effect.
[0070] The anti-obesity effect of the extract of the above-mentioned Paeonia suffruticosa underground part is, for example, exerted by one or more effects selected from the group consisting of cyclic AMP-phosphonodiesterase activity inhibitory effect, differentiation induction promotion effect of preadipocytes, fat accumulation inhibition effect and cell death induction effect of adipocytes. Therefore, the above-mentioned anti-obesity agent preferably has one or more effects selected from the group consisting of cyclic AMP-phosphonodiesterase activity inhibitory effect, differentiation induction promotion effect of preadipocytes, fat accumulation inhibition effect and cell death induction effect of adipocytes. In addition, the anti-obesity effect of the extract of the above-mentioned Paeonia suffruticosa underground part is not limited to one or more effects selected from the group consisting of cyclic AMP-phosphonodiesterase activity inhibitory effect, differentiation induction promotion effect of preadipocytes, fat accumulation inhibition effect and cell death induction effect of adipocytes.
[0071] Furthermore, the present invention also relates to a cyclic AMP-phosphodiesterase activity inhibitor, a pre-adipocyte differentiation induction promoter, a fat accumulation inhibitor, or an adipocyte cell death inducer containing the extract of the above-mentioned Paeonia suffruticosa underground part.
[0072] (Composition for eliminating obesity)
[0073] The anti-obesity composition of the present invention contains the anti-obesity agent of the present invention and further contains other components as necessary.
[0074] <Anti-obesity drugs>
[0075] The above-mentioned anti-obesity agent is the anti-obesity agent of the present invention.
[0076] The content of the above-mentioned anti-obesity agent in the above-mentioned anti-obesity composition is not particularly limited, and can be appropriately adjusted according to the form of the above-mentioned anti-obesity composition, the physiological activity of the above-mentioned Paeonia suffruticosa extract, etc., and is preferably 0.0001% by mass to 20% by mass, and more preferably 0.0001% by mass to 10% by mass when converted into the amount of the above-mentioned Paeonia suffruticosa extract. The above-mentioned anti-obesity composition can be formed only by the above-mentioned anti-obesity agent.
[0077] <Other ingredients>
[0078] As other components in the above-mentioned composition for eliminating obesity, there is no particular restriction, and it can be appropriately selected according to the utilization form of the above-mentioned composition for eliminating obesity, for example, the same components as other components recorded in the project of the above-mentioned anti-obesity agent can be cited, etc. They can be used alone or in combination of two or more.
[0079] The content of the other components in the obesity-eliminating composition is not particularly limited and can be appropriately selected depending on the intended purpose.
[0080] <Method>
[0081] The form of the composition for eliminating obesity is not particularly limited and can be appropriately selected depending on the purpose. Examples thereof include pharmaceuticals, cosmeceuticals, food and drink, and cosmetics.
[0082] The composition for eliminating obesity of the present invention can be used daily, and can extremely effectively exert various physiological activities including the eliminating obesity effect, due to the effect of the extract of the underground part of Paeonia suffruticosa as an effective ingredient.
[0083] The obesity-eliminating composition of the present invention is suitable for use in humans, but can also be used in animals other than humans (eg, mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as their respective effects are exerted.
[0084] The usage of the composition for eliminating obesity of the present invention is not particularly limited and can be appropriately selected depending on the purpose. For example, the usage may be oral, parenteral, or external use.
[0085] As the above-mentioned oral composition, for example, the above-mentioned oral administration agent and food and drink can be cited. Here, food and drink refers to substances that are less harmful to human health and are taken by oral or digestive tract administration in ordinary social life, and are not limited to administrative divisions such as food, pharmaceuticals, and cosmetics. Therefore, the above-mentioned food and drink refers to a large number of food and drink that constitute general food, health food (functional food and drink), health functional food (specific health food, nutritional functional food, functional display food), cosmetics, and pharmaceuticals that are taken orally.
[0086] There is no particular limitation on the type of the composition for oral administration, and it can be appropriately selected according to the purpose. For example, beverages such as tea beverages, refreshing drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, alcoholic drinks, coffee drinks, and refreshing drinks with coffee added thereto (including concentrated stock solutions of these beverages and powders for adjustment); frozen desserts such as ice cream, sherbet, and shaved ice; noodles such as soba noodles, udon noodles, vermicelli noodles, dumpling wrappers, shao mai wrappers, Chinese noodles, and instant noodles; sugar, candy, chewing gum, chocolate, block desserts, packaged desserts, biscuits, jelly, jam, cream, baked goods, etc. Pastries, bread and other snacks; crab, salmon, clams, tuna, sardines, shrimp, bonito, mackerel, whale, oyster, saury, squid, red clam, scallop, abalone, sea urchin, salmon roe, abalone and other aquatic products; fish paste, ham, sausage and other aquatic and livestock processed foods; processed milk, fermented milk and other dairy products; salad oil, tempura oil, margarine, mayonnaise, shortening, fresh cream, sauce and other fats and fat processed foods; seasonings, sauces and other condiments; curry, stew, parent-child rice bowl, porridge, rice gruel, Chinese rice bowl, pork cutlet rice bowl, tempura rice bowl, eel rice bowl, hash rice bowl (hash Rice), oden, mapo tofu, beef rice, meat sauce, egg soup, fried egg rice, dumplings, siomai, hamburgers, meatballs and other retort bags; salads, pickles and other home-cooked dishes; various forms of health, beauty, and nutritional supplements; tablets, granules, capsules, beverages, lozenges, mouthwashes and other pharmaceutical products, medical cosmetics; mouth fresheners for use in the mouth, such as mouth fresheners and anti-bad breath agents, toothpaste, etc.
[0087] As compositions other than the above-mentioned oral use, for example, the above-mentioned parenteral administration agents and external preparations can be mentioned. For example, ointments, creams, lotions, toners, facial masks, foundations, etc. can be used as skin cosmetics, and hair tonics, hair creams, hair dyes, shampoos, hair oils, hair dyes, etc. can be used as hair cosmetics.
[0088] The method for producing the above-mentioned composition for eliminating obesity is not particularly limited, and can be appropriately selected according to the form of use of the above-mentioned composition for eliminating obesity, etc.
[0089] The amount of the composition for eliminating obesity used, the period of use, etc. are not particularly limited and can be appropriately selected depending on the intended purpose.
[0090] As described above, the anti-obesity agent and anti-obesity composition of the present invention have excellent anti-obesity effects.
[0091] Therefore, the present invention also relates to a method for eliminating obesity, characterized in that at least one of the above-mentioned anti-obesity agent and anti-obesity composition is administered to an individual.
[0092] Example
[0093] Hereinafter, production examples, test examples, and formulation examples of the present invention will be described, but the present invention is not limited to these production examples, test examples, and formulation examples.
[0094] Test samples used in Test Examples 1 to 4 described below were produced as follows.
[0095] (Production Example 1: 30% ethanol extract of Paeonia suffruticosa root)
[0096] An extract of the underground part of Paeonia suffruticosa L. using 30% by volume ethanol was produced as follows.
[0097] 200 mL of 30% by volume ethanol was added to 10 g of the underground part of Paeonia suffruticosa, and the mixture was extracted at 80° C. for 1 hour using a reflux cooler, and then filtered with filter paper to obtain an extract.
[0098] The obtained extract was concentrated under reduced pressure and dried to obtain 2.28 g of a 30% by volume ethanol extract (powder) of the underground part of Paeonia suffruticosa.
[0099] (Production Example 2: 50% ethanol extract of Paeonia suffruticosa root)
[0100] An extract of the underground part of Paeonia suffruticosa L. with 50% by volume ethanol was produced as follows.
[0101] In Preparation Example 1, except that 30% by volume ethanol was replaced with 50% by volume ethanol, the same operation as in Preparation Example 1 was performed to obtain 2.23 g of a 50% by volume ethanol extract (powder) of the underground part of Paeonia suffruticosa. (Preparation Example 3: 80% ethanol extract of the underground part of Paeonia suffruticosa)
[0102] An extract of the underground part of Paeonia suffruticosa L. using 80% by volume ethanol was produced as follows.
[0103] In Preparation Example 1, except that 30% by volume ethanol was replaced with 80% by volume ethanol, the same operation as in Preparation Example 1 was carried out to obtain 1.90 g of an 80% by volume ethanol extract (powder) of the underground part of Paeonia suffruticosa. (Comparative Preparation Example 1: 30% ethanol extract of the aerial part of Paeonia suffruticosa)
[0104] An extract of the aerial part of Paeonia suffruticosa L. using 30% by volume ethanol was prepared as follows.
[0105] In Production Example 1, 10 g of the underground part of Paeonia suffruticosa was replaced with 30 g of the above-ground part of Paeonia suffruticosa, and 200 mL of 30 vol % ethanol was replaced with 600 mL of 30 vol % ethanol. Except for this, the same operation as Production Example 1 was carried out to obtain 10.48 g of 30 vol % ethanol extract (powder) of the above-ground part of Paeonia suffruticosa.
[0106] (Comparative Preparation Example 2: 50% ethanol extract of Paeonia suffruticosa aerial parts)
[0107] An extract of the aerial part of Paeonia suffruticosa L. using 50% by volume ethanol was prepared as follows.
[0108] 10.28 g of a 50 vol % ethanol extract (powder) of the aerial part of Paeonia suffruticosa was obtained in the same manner as in Comparative Production Example 1 except that 30 vol % ethanol was replaced with 50 vol % ethanol.
[0109] (Comparative Preparation Example 3: 80% ethanol extract of Paeonia suffruticosa aerial parts)
[0110] An extract of the aerial part of Paeonia suffruticosa L. using 80% by volume ethanol was produced as follows.
[0111] 9.27 g of a 80% by volume ethanol extract (powder) of the aerial part of Paeonia suffruticosa was obtained in the same manner as in Comparative Production Example 1 except that 30% by volume ethanol was replaced with 80% by volume ethanol.
[0112] (Test Example 1-1: Determination of Terpene Lactone Content)
[0113] The terpene lactone content of each of the Paeonia suffruticosa extracts produced in Production Examples 1 to 3 and Comparative Production Examples 1 to 3 was measured in the following manner.
[0114] <Preparation of analytical samples>
[0115] 10 mg of each sample was accurately weighed in a 10 mL measuring flask, and the volume was fixed to 10 mL with 50% acetonitrile (ACN). The liquid was filtered through a 0.45 μm hydrophilic polytetrafluoroethylene (PTFE) membrane filter to obtain a sample solution.
[0116] The standard substance used was (+)-pterin (ChemFaces, Lot. CFS201901, purity 98% or more), and the purity was 100% to quantify terpene lactones (Hyuganin D, hyogamin III, cis-3'-acetyl-4'-tegumentyl lactone, trans-3'-acetyl-4'-senecioide, hyogamin II, isopyrimidine, pterin). The amount weighed was about 2 mg.
[0117] <HPLC analysis conditions>
[0118] Column: Wakosil II 5C18AR, 4.6 mm × 250 mm (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)
[0119] Mobile phase: 0.1% TFA (A): ACN (B) 0-45min (41% B)
[0120] Flow rate: 1.0mL / min
[0121] Oven temperature: 40℃
[0122] Injection volume: 20 μL
[0123] Detection: 320nm
[0124] Table 1-1 below shows the terpene lactone content (pterin equivalent value) in each of the Paeonia suffruticosa extracts produced in Production Examples 1 to 3 and Comparative Production Examples 1 to 3.
[0125] [Table 1-1]
[0126]
[0127] A:Hyuganin D
[0128] B: Valium Coumarin III
[0129] C: cis-3'-acetyl-4'-tetramethylolactone
[0130] D: trans-3'-acetyl-4'-seneciolide
[0131] E: diazepam coumarin II
[0132] F: Isopyrimidine
[0133] G: Pterin
[0134] (Test Example 1-2: Determination of Chlorogenic Acid Content and Rutin Content)
[0135] The chlorogenic acid content and the rutin content of each of the Paeonia suffruticosa extracts produced in the above-mentioned Production Examples 1 to 3 and Comparative Production Examples 1 to 3 were measured in the following manner.
[0136] <Preparation of analytical samples>
[0137] 10 mg of each sample was accurately weighed into a 10 mL measuring flask, and the volume was fixed to 10 mL with 20% methanol. The liquid was filtered through a 0.45 μm hydrophilic polytetrafluoroethylene (PTFE) membrane filter to obtain a sample solution.
[0138] Chlorogenic acid (MP Biomedical) and rutin (Fujifilm Wako Pure Chemical Industries, Ltd.) were used as standard substances, and the chlorogenic acid and rutin in the sample solution were quantified as 100% purity. The amount weighed was about 5 mg.
[0139] <HPLC analysis conditions>
[0140] Column: Wakosil II 5C18AR, 4.6 mm × 250 mm (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.)
[0141] Mobile phase: 0.1% TFA (A): ACN (B)
[0142] 0-25min (7-30% B),
[0143] 25.01-30min(90%B)
[0144] 30.01-40min (7% B)
[0145] Flow rate: 1.0mL / min
[0146] Oven temperature: 30℃
[0147] Injection volume: 5μL, 10μL, 20μL
[0148] Detection: 330nm (chlorogenic acid), 350nm (rutin)
[0149] The following Table 1-2 shows the chlorogenic acid content and rutin content in each of the Paeonia suffruticosa extracts produced in the above-mentioned Production Examples 1 to 3 and Comparative Production Examples 1 to 3.
[0150] [Table 1-2]
[0151]
[0152] (Test Example 2: Cyclic AMP-phosphonodiesterase activity inhibition test)
[0153] The cyclic AMP-phosphonodiesterase activity inhibitory effect was tested by the following test method using each of the Paeonia suffruticosa extracts produced in the above-mentioned Production Examples 1 to 3 and Comparative Production Examples 1 to 3 as test samples.
[0154] To 0.2 mL of 50 mmol / L Tris-HCl buffer (pH 7.5) containing 5 mmol / L magnesium chloride, 0.1 mL of 2.5 mg / mL bovine serum albumin solution, 0.1 mL of 0.1 mg / mL cyclic AMP-phosphodiesterase solution, and 0.05 mL of a test sample solution (refer to Table 2 below for sample concentration) were added, and the mixture was allowed to stand at 37°C for 5 minutes to perform a preliminary reaction. To this, 0.05 mL of 0.5 mg / mL cyclic AMP (cAMP) solution was added, and the mixture was reacted at 37°C for 60 minutes. Then, the mixture was boiled in a boiling water bath for 3 minutes to stop the reaction, and the mixture was centrifuged (2,260 × g, 10 minutes, 4°C), and cyclic AMP as a reaction substrate in the supernatant was analyzed by high-performance liquid chromatography (HPLC) under the following conditions. In addition, as a control, only the sample without the addition of solvent was added, and the same operation was performed.
[0155] <HPLC conditions>
[0156] Pump: DP-8020 (Tosoh Corporation)
[0157] ·UV-visible detector: UV-8020 (Tosoh Corporation)
[0158] ·Integrator: Chromatocoder 21 (Tosoh Corporation)
[0159] ·Column oven: CO-8020 (Tosoh Corporation)
[0160] Online degasser: SD-8022 (Tosoh Corporation)
[0161] Column: Wakosil C18-ODS 5μm (Fujifilm Wako Pure Chemical Industries, Ltd.)
[0162] Mobile phase: 1mmol / L TBAP in 25mmol / L KH 2 PO 4 :CH 3 CN=90:10
[0163] Flow rate: 1.0mL / min
[0164] Detection: 260nm
[0165] Atten: 128
[0166] Next, the peak area (A) of the cyclic AMP standard, the peak area (B1) of the supernatant of the reaction solution of the cyclic AMP standard and cyclic AMP-phosphodiesterase when no test sample is added, and the peak area (B2) of the supernatant of the reaction solution of the cyclic AMP standard and cyclic-AMP phosphodiesterase when the test sample is added are determined. From the obtained results, the decomposition rate (C) of the cyclic AMP standard when no test sample is added and the decomposition rate (D) of the cyclic AMP standard when the test sample is added are calculated by the following formula.
[0167] Decomposition rate of cyclic AMP standard when no sample is added (C) (%) = (1-B1 / A) × 100
[0168] Decomposition rate of cyclic AMP standard when the test sample is added (D) (%) = (1-B2 / A) × 100
[0169] Then, based on the respective degradation rates (C, D) calculated from the above formula, the cyclic AMP-phosphodiesterase activity inhibition rate (%) was calculated from the following formula.
[0170] Cyclic AMP-phosphodiesterase activity inhibition rate (%) = (1-D / C) × 100
[0171] [Table 2]
[0172]
[0173] From the results in Table 2, it was confirmed that the extract from the underground part of Paeonia suffruticosa had an excellent inhibitory effect on the activity of cyclic AMP-phosphonodiesterase.
[0174] (Test Example 3: Test on the effect of promoting differentiation induction using human visceral adipocytes)
[0175] The differentiation induction promoting effect was tested by the following test method using each of the Paeonia suffruticosa extracts produced in the above-mentioned Production Examples 1 to 6 as test samples.
[0176] Human visceral preadipocytes were used to generate 75 cm 2 Flasks were incubated in proliferation medium (PGM Bullet Kit (Takara Bio Co., Ltd.)) at 37°C, 5% CO 2 The cells were collected by trypsin treatment.
[0177] Using the PGM Bullet Kit, 2.5 × 10 cells were seeded per well on a collagen-coated 96-well plate (IWAKI). 3 cells / 200 μL, at 37°C, 5% CO 2After culturing, discard the culture medium and replace it with differentiation induction medium. At the same time, add the test sample supplement medium at a predetermined concentration and incubate at 37°C and 5% CO. 2 The culture was continued for 7 days at 4 °C. The culture supernatant was discarded and the cells were further cultured for 8 days using the PGM Bullet Kit.
[0178] After the culture was completed, the culture medium was discarded and intracellular triglyceride (TG) was analyzed using AdipoRed TM Then, protein was extracted by M-PER Mammalian Protein Extraction Reagent (PIERCE Biotechnology, Inc.), and protein was quantified using BCA Protein Assay Reagent Kit (PIERCE Biotechnology, Inc.).
[0179] The results are shown in Table 3. In addition, each numerical value (%) in Table 3 represents a relative value, with the amount in differentiated cells to which no test sample was added being represented as 100%.
[0180] [Table 3]
[0181]
[0182] As shown in Table 3, it was confirmed that the amount of TG per unit protein amount was further increased when the extract of the underground part of Paeonia suffruticosa was added, and that the extract of the underground part of Paeonia suffruticosa had an excellent effect of promoting the differentiation induction of human visceral preadipocytes.
[0183] (Test Example 4: Test on fat accumulation inhibitory effect and cell death inducing effect using human visceral adipocytes)
[0184] The extracts of Paeonia suffruticosa produced in the above-mentioned Production Examples 1 to 3 and Comparative Production Examples 1 to 3 were used as test samples, and the fat accumulation inhibitory effect and cell death inducing effect were tested by the following test methods.
[0185] Human visceral preadipocytes were used to generate 75 cm 2 Flasks were incubated in proliferation medium (PGM Bullet Kit (Takara Bio Co., Ltd.)) at 37°C, 5% CO 2 The cells were collected by trypsin treatment.
[0186] Using the PGM Bullet Kit, 2.5 × 10 cells were seeded per well on a collagen-coated 96-well plate (IWAKI). 3cells / 200 μL, at 37°C, 5% CO 2 After culturing, discard the culture medium and replace it with differentiation induction medium at 37°C and 5% CO. 2 The culture supernatant was discarded and replaced with a medium containing a test sample at a predetermined concentration, and the culture was continued for another 8 days.
[0187] After the culture was completed, the culture medium was discarded and intracellular triglyceride (TG) was analyzed using AdipoRed TM Then, protein was extracted by M-PER Mammalian Protein Extraction Reagent (PIERCE Biotechnology, Inc.), and protein quantification was performed using BCA Protein Assay Reagent Kit (PIERCE Biotechnology, Inc.).
[0188] The results are shown in Table 4. In addition, each numerical value (%) in Table 4 represents a relative value, with the amount in differentiated cells to which no test sample was added being represented as 100%.
[0189] [Table 4]
[0190]
[0191] As shown in Table 4, it was confirmed that when the extract of the underground part of Paeonia suffruticosa was added, the TG amount per unit protein amount was further reduced, and the extract of the underground part of Paeonia suffruticosa had an excellent fat accumulation inhibitory effect. In addition, it was confirmed that when the extract of the underground part of Paeonia suffruticosa was added, the protein amount was also reduced, and the extract of the underground part of Paeonia suffruticosa had an excellent cell death inducing effect.
[0192] (Production Example 4: 50% ethanol extract of Paeonia suffruticosa root)
[0193] In the same manner as in Production Example 2, 1.70 g of a 50% by volume ethanol extract (powder) of the underground part of Paeonia suffruticosa was obtained.
[0194] The extract obtained in Preparation Example 4 was subjected to the same operation as in Test Example 1-1 to measure the terpene lactone content. The results are as follows.
[0195] <Terpene lactone content>
[0196] ·Hyuganin D···0.13 mass%
[0197] ·Stabilized coumarin III···0.33 mass%
[0198] ·cis-3'-acetyl-4'-tetrahydrotyrilactone···0.30 mass%
[0199] · trans-3'-acetyl-4'-seneciolide···0.28 mass%
[0200] ·Stabilized coumarin II···0.015 mass%
[0201] ·Isopyrimidine···0.049 mass%
[0202] ·Pterin···1.16 mass%
[0203] Total: 2.26% by mass
[0204] The extract obtained in Preparation Example 4 was subjected to the same operation as in Test Example 1-2 to measure the chlorogenic acid content and the rutin content. The results are as follows.
[0205] ·Chlorogenic acid···0.80 mass%
[0206] ·Rutin···0.015 mass%
[0207] In addition, the extract obtained in Preparation Example 4 was tested for various effects in the same manner as in Test Examples 2 to 4. As a result, the same effects as those of the extract in Preparation Example 2 were confirmed.
[0208] (Matching Example 1)
[0209] Tablets having the following composition were produced by a conventional method.
[0210]
[0211] (Matching Example 2)
[0212] An oral liquid preparation having the following composition was produced by a conventional method.
[0213] <Composition of 1 ampoule (100 mL)>
[0214]
[0215] (Matching Example 3)
[0216] By a conventional method, particles having the following composition were produced.
[0217]
[0218]
[0219] (Matching Example 4)
[0220] By conventional methods, soft capsules having the following composition were produced.
[0221]
[0222] (Matching Example 5)
[0223] By a conventional method, chocolate having the following composition was produced.
[0224]
[0225] (Matching Example 6)
[0226] Refreshing drinking water having the following composition was produced by a conventional method.
[0227]
[0228]
[0229] This application claims the priority based on Japanese Patent Application No. 2022-040345 filed on March 15, 2022, and all contents of Japanese Patent Application No. 2022-040345 are incorporated herein by reference.
Claims
1. An anti-obesity agent, characterized in that: Contains extract from the underground parts of Paeonia suffruticosa.
2. The anti-obesity agent according to claim 1, The extract of the underground part of Paeonia suffruticosa is an extract obtained by using a mixed solvent of water and a hydrophilic solvent.
3. The anti-obesity agent according to claim 1 or 2, The extract of the underground part of Paeonia suffruticosa contains, as terpene lactones, Hyuganin D, peucedanocoumarin III, cis-3'-acetyl-4'-tigloylkhellactone, trans-3'-acetyl-4'-senecioylkhellactone, isosamidin and pteryxin.
4. The anti-obesity agent according to any one of claims 1 to 3, The compound has one or more effects selected from the group consisting of an effect of inhibiting cyclic AMP-phosphonodiesterase activity, an effect of promoting the induction of differentiation of preadipocytes, an effect of suppressing fat accumulation, and an effect of inducing cell death of adipocytes.
5. A composition for eliminating obesity, characterized in that: A method comprising the anti-obesity agent according to any one of claims 1 to 4.
